AstraZeneca PLC (AZNCF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 09:30AM EDT
| Previous Close | 135.30 |
| Open | 140.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 140.15 - 140.15 |
| 52 Week Range | 118.16 - 153.10 |
| Volume | |
| Avg. Volume | 3,025 |
| Market Cap | 217.263B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 36.78 |
| EPS (TTM) | 3.81 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.86 (2.04%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
ZacksAstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
ZacksPharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
© 2024 Yahoo. All rights reserved.